Skip Navigation


Annals of Oncology Advance Access originally published online on April 29, 2007
Annals of Oncology 2007 18(8):1348-1353; doi:10.1093/annonc/mdm136
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/8/1348    most recent
mdm136v2
mdm136v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferrandina, G
Right arrow Articles by Scambia, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrandina, G
Right arrow Articles by Scambia, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gynecologic tumors

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

G Ferrandina1,2,*, M Ludovisi1, R De Vincenzo1, V Salutari1, D Lorusso2, M Colangelo3, T Prantera4, MR Valerio5 and G Scambia2

1 Gynecologic Oncology Unit, Catholic University of Rome, Rome
2 Department of Oncology, Catholic University of Campobasso, Campobasso
3 Medical Oncology, SS. Annunziata Hospital, Sulmona
4 Medical Oncology, San Giovanni di Dio Hospital, Crotone
5 Department of Oncology, University of Palermo, Palermo, Italy

* Correspondence to: Dr G. Ferrandina, Gynecologic Oncology Unit, Catholic University, L.go A. Gemelli, 8 00168, Rome. Tel/Fax: +39-06-3550-8736; E-mail: gabriella.ferrandina{at}libero.it

Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12 months.

Patients and methods: DTX, 75 mg/m2, was administered by 60 min i.v. infusion, followed by OXA, 100 mg/m2, given by a 2 h i.v., on day 1 every 21 days.

Results: From October 2003 to June 2006, 43 ovarian cancer patients were enrolled. Median PFI was 26 months. All patients were available for response evaluation: 17 complete responses and 12 partial responses were registered, for an overall response rate of 67.4%. The median response duration was 10 months. Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of 259 courses were administered. Grade 3–4 leukopenia was documented in 32.5% of the patients, while no case of severe anemia and thrombocytopenia was observed. Grade 3–4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% of cases, respectively.

Conclusion: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian cancer patients.

Key words: docetaxel, ovarian cancer recurrence, oxaliplatin

Received for publication January 2, 2007. Revision received March 4, 2007. Revision received March 19, 2007. Accepted for publication March 22, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.